Catalyst Wire Dossier Catalyst Wire Dossier

CYNK-101

· Celularity Incorporated
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CYNK-101, covering 2024-12-12 to 2024-12-12. Get the full timeline:

Most recent: Clinical Trial Update: CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma [Phase 1, Phase 2]

See pricing